Q1 2025 EPS Estimates for Incyte Co. (NASDAQ:INCY) Boosted by William Blair

Incyte Co. (NASDAQ:INCY) – Analysts at William Blair increased their Q1 2025 earnings per share (EPS) estimates for Incyte in a report issued on Tuesday, April 23rd. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $0.90 for the quarter, up from their previous forecast of $0.71. William Blair has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $3.85 per share.

Other research analysts have also issued reports about the company. Citigroup lowered their price target on Incyte from $82.00 to $81.00 and set a “buy” rating for the company in a research report on Wednesday, February 14th. Cantor Fitzgerald assumed coverage on Incyte in a report on Tuesday. They issued a “neutral” rating for the company. Bank of America decreased their target price on Incyte from $69.00 to $67.00 and set a “neutral” rating for the company in a report on Wednesday, March 13th. Oppenheimer decreased their target price on Incyte from $92.00 to $84.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $65.00 target price on shares of Incyte in a report on Monday, March 25th. Nine investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $75.50.

Incyte Trading Up 1.0 %

INCY opened at $51.68 on Thursday. Incyte has a 52 week low of $50.27 and a 52 week high of $75.74. The business has a fifty day simple moving average of $56.78 and a 200-day simple moving average of $57.70. The firm has a market cap of $11.60 billion, a P/E ratio of 19.50, a P/E/G ratio of 1.20 and a beta of 0.65. The company has a quick ratio of 3.36, a current ratio of 3.55 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.09). Incyte had a return on equity of 12.56% and a net margin of 16.17%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the business earned $0.44 earnings per share. The company’s quarterly revenue was up 9.3% on a year-over-year basis.

Institutional Trading of Incyte

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Pinnacle Associates Ltd. acquired a new stake in shares of Incyte during the first quarter worth about $3,035,000. Mesirow Financial Investment Management Inc. acquired a new stake in shares of Incyte during the first quarter worth about $396,000. New York State Teachers Retirement System increased its position in shares of Incyte by 1.9% during the first quarter. New York State Teachers Retirement System now owns 203,649 shares of the biopharmaceutical company’s stock worth $11,602,000 after purchasing an additional 3,739 shares in the last quarter. Capital Investment Advisory Services LLC acquired a new stake in shares of Incyte during the first quarter worth about $318,000. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of Incyte by 24.6% during the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 115,364 shares of the biopharmaceutical company’s stock worth $6,572,000 after purchasing an additional 22,800 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.